Melatonin Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Melatonin dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Melatonin.
Dosing Protocols
The Beginner Protocol targets the most common use case: sleep-onset difficulty in adults without serious circadian disorders, new users establishing baseline response, and jet-lag prevention.
Starting dose: 0.3-0.5mg immediate-release melatonin, taken 30-60 minutes before desired sleep onset. Most OTC melatonin is sold in 3mg, 5mg, or 10mg tablets — these are supraphysiological doses for this starting protocol. Practical options: (1) buy a dedicated low-dose 0.3mg or 0.5mg product (widely available online and from specialty pharmacies), (2) cut 3mg tablets into quarters (approximately 0.75mg per quarter), (3) choose a reputable brand's 0.5mg or 1mg product.
Week 1-2 (baseline establishment): Take 0.5mg melatonin 30-60 minutes before desired sleep onset. Maintain consistent timing within 30 minutes night-to-night. Keep a brief sleep log noting: time to sleep onset, number of wake-ups, subjective sleep quality (1-10), morning alertness on waking (1-10), any side effects. After 7-14 nights, evaluate: most users at this dose experience modest improvements in sleep onset latency (10-15 minutes faster) without morning grogginess.
Week 3 adjustment: If sleep onset is improved but sleep quality/duration is still suboptimal, the issue is often architecture rather than onset — consider adding Magnesium glycinate 200-400mg or Glycine 3g alongside the melatonin rather than increasing the melatonin dose. If sleep onset isn't improved, consider: (1) increasing dose to 1mg, (2) moving timing to 90 minutes before bed, (3) adding light management (morning bright light + evening dim/blue-blocking lighting) which dramatically enhances melatonin's effect, (4) evaluating for caffeine interference (must cut off 6-8h before bed), alcohol use, or underlying circadian disorder.
Jet lag preparation: for eastward travel across 3+ time zones, begin melatonin 1-3 days before departure at the destination-time-zone bedtime equivalent. On arrival, continue 0.5-3mg at local bedtime for 2-4 nights, with morning bright light exposure at destination. This is the best-evidenced use case for melatonin (Herxheimer 2001 Cochrane review).
Westward travel: phase-delay needs are usually met by light exposure and bedtime delay; evening melatonin is less useful and may be counterproductive. Morning melatonin is rarely used in non-blind travelers.
Workplace shift adaptation: if transitioning to night shift, evening melatonin before pre-shift sleep (the sleep period preceding night work) at 0.5-1mg can help consolidate that sleep. Evening pre-shift sleep should also include full darkness during sleep (blackout curtains, sleep mask) to avoid melatonin suppression from home daytime light.
What to avoid in the Beginner Protocol: (1) doses above 3mg — provides no additional benefit and produces morning grogginess in most users; (2) daytime use for anxiolysis — disrupts circadian rhythm; (3) combining with fluvoxamine, ciprofloxacin, or other strong CYP1A2 inhibitors without dose reduction; (4) indefinite nightly use without periodic reassessment — 3-6 months then re-evaluate ongoing need; (5) use during pregnancy, lactation, or active fertility-seeking cycle without physician guidance.
Red flags to stop and consult a physician: sleep difficulties persisting >4 weeks despite melatonin and behavioral measures, dramatic deterioration in sleep quality, new daytime sedation, mood decline, paradoxical insomnia that doesn't resolve with dose reduction. Persistent insomnia warrants formal sleep evaluation — including assessment for sleep apnea, restless legs syndrome, depression/anxiety, and chronobiotic disorders — rather than indefinite melatonin escalation.
The Intermediate Protocol addresses specific circadian-rhythm applications and combination stacks for users with baseline melatonin experience.
Delayed sleep phase syndrome (DSPS) protocol: for individuals with habitual sleep onset >2 hours later than conventional desired bedtime, combined with morning waking difficulty and best sleep on free schedules.
Weeks 1-4 (active phase advance):
- Take melatonin 0.3-0.5mg approximately 5-7 hours before habitual current sleep onset (not target bedtime). For a 3am habitual sleep onset, this means 8-10pm melatonin dosing. This is the critical difference from primary insomnia protocol — the timing produces phase advance rather than acute sleep induction.
- Simultaneously: morning bright light exposure 30-60 minutes of 10,000 lux or outdoor sunlight within 30 minutes of desired wake time, 5-7 days per week. This is as important as the melatonin for DSPS correction.
- Maintain strict sleep-wake timing — same bedtime and wake time every day including weekends. Weekend drift undoes weekday gains.
- Gradually advance bedtime by 15-30 minutes per week as melatonin dosing time simultaneously advances.
- Evening dim lighting, blue-light blocking 2+ hours before bed.
- Avoid caffeine after noon.
Weeks 5-8 (consolidation): once target bedtime is achieved, continue melatonin at 0.3-0.5mg 30-60 minutes before bedtime (no longer 5-7 hours advance), continue morning light, and maintain timing rigidity for at least 4-8 weeks to consolidate the phase shift.
Weeks 9+ (maintenance/taper): consider reducing melatonin to every other night or weekend-only after 2-3 months of stable phase. DSPS tends to recur without maintenance of morning light and sleep-timing discipline.
REM sleep behavior disorder (RBD) protocol: for diagnosed RBD with dream enactment and injury risk — requires sleep specialist confirmation of diagnosis first.
- Start melatonin 3mg at bedtime, increasing by 3mg increments every 2 weeks as needed for symptom control.
- Typical effective dose 6-12mg nightly.
- Extended-release formulation often preferred for overnight coverage.
- Morning alertness should be monitored — if excessive grogginess, consider earlier dosing (9pm vs 11pm) or lower dose.
- Bedroom safety modifications (bed padding, partner sleep separation, removal of bedside objects) remain important regardless of pharmacology.
- Concurrent neurological evaluation essential given RBD's association with Parkinson/Lewy body disease development; melatonin is symptom management, not disease modification.
Pediatric ASD/ADHD sleep protocol: under pediatrician direction.
- Start at 1mg 30-60 minutes before bedtime for children 4-10 years, 2-3mg for adolescents.
- Extended-release pediatric formulation (Slenyto 1mg, 2mg, 5mg) used in EU, compounded options in US.
- Combined with consistent sleep hygiene, wind-down routines, and screen curfew.
- Monitor for morning grogginess, paradoxical effects, and next-day behavior.
- Re-evaluate need every 3-6 months — some children experience spontaneous resolution with development.
- Long-term pediatric safety beyond 5 years has limited data; periodic holidays or reassessment reasonable.
Combination sleep-architecture stack for persistent insomnia: after verifying no sleep apnea, RLS, or depression contribution.
- Melatonin 0.3-1mg + Magnesium glycinate 300-400mg elemental Mg 30-60 min before bed
-
- Glycine 3g sublingual or dissolved 30 min before bed (for reduced sleep onset latency and subjective sleep quality per Inagawa 2006)
-
- L-theanine 200mg if anxious-mind sleep difficulty
- Morning bright light exposure
- Strict caffeine cutoff 2pm
- Screen curfew 1-2 hours before bed or blue-blocking glasses
Migraine prophylaxis protocol (Gonçalves 2016, PMID: 27165014 as evidence base):
- Melatonin 3mg at bedtime nightly for 3 months
- Compare to baseline migraine diary for attack frequency, duration, severity
- Response typically apparent by 6-8 weeks; if no response at 3 months, discontinue
- If responder, continue 3mg nightly indefinitely with periodic reassessment
- Neurologist supervision recommended for chronic migraine management
Cycling and tolerance management: for users taking melatonin nightly >3 months, consider periodic cycling — 1 week off every 8-12 weeks, or weekend holidays (no melatonin Friday-Sunday). This maintains receptor sensitivity and serves as diagnostic "off-period" to assess whether melatonin is still providing benefit. If sleep is equally good off melatonin, taper permanently.
The Advanced Protocol covers high-dose oncology adjunctive use, blind non-24-hour disorder management, and specialized chronobiotic applications — all requiring physician supervision.
Oncology adjunctive protocol: based on Seely et al. 2012 meta-analysisand selected integrative oncology protocols, primarily for hormone-sensitive breast, prostate, and gastrointestinal cancers as adjunct to standard therapy.
- Dose range: 10-40mg melatonin nightly, typically given as 20mg immediate-release at bedtime
- Some protocols use higher doses (40-100mg) in advanced disease
- Timing: bedtime administration to leverage overnight high-exposure for oncostatic mechanisms
- Duration: typically continued throughout active treatment and into survivorship
- Monitoring: morning cortisol, reproductive hormones if premenopausal, CBC, liver function
- Drug interactions: particularly relevant with tamoxifen (melatonin-estrogen interaction complex), chemotherapy (potential mitochondrial-protective effect on healthy tissues), immunotherapy (theoretical immunomodulation)
- This use requires discussion with oncology team; not standard-of-care but increasingly included in integrative protocols with reasonable safety profile
- Not recommended for: active immunosuppression in autoimmune disease treatment, active solid-organ transplant recipients
Non-24-hour sleep-wake disorder in totally blind individuals: management of the circadian drift that occurs in absence of light entrainment.
- Dose: 0.5-3mg melatonin taken at the same clock time each night, 1 hour before desired sleep onset
- Duration: indefinite — this is chronic therapy, not transient correction
- Tasimelteon (Hetlioz) is FDA-approved alternative, may be preferred for insurance coverage or for patients with melatonin intolerance
- Requires chronobiotic specialist or endocrinology supervision
- Dim light melatonin onset (DLMO) measurement if available helps confirm entrainment; sleep diary provides clinical endpoint
Shift work disorder (chronic night-shift workers):
- Complex protocol requiring individualized timing based on shift pattern and personal chronotype
- For permanent night shift: morning melatonin 1-3mg upon arrival home (which is "evening" for the worker's biological schedule) with full darkness during daytime sleep
- For rotating shifts: melatonin protocol varies per rotation direction
- This is a specialized chronobiotic application; occupational medicine or sleep specialist guidance recommended
- Combined approach with carefully timed light therapy produces best results
- Not curative — shift-work-related health risks persist regardless of melatonin use
Pre-operative protocol in adults (increasingly studied for anxiolysis and sleep architecture protection through surgery):
- Melatonin 3-6mg evening before and 1-2 hours before surgery
- May reduce pre-operative anxiety and post-operative delirium in some populations
- Discuss with anesthesia; consider interactions with anesthetic sensitivity
Traumatic brain injury sleep disruption:
- Immediate-release or extended-release melatonin 1-3mg at bedtime
- Evidence limited but biological rationale strong given melatonin's mitochondrial-protective and neuroprotective properties
- TBI specialist or neurology guidance
Cluster headache prevention: small trials suggest melatonin 10mg at bedtime may reduce cluster headache frequency; not first-line but consideration for patients intolerant to verapamil or other first-line options; neurology supervision.
Advanced cycling and drug-holiday protocols for long-term users:
- Every 8-12 weeks: 1-2 week complete melatonin cessation to reassess receptor sensitivity and ongoing need
- Drug holidays during travel or stress periods not advisable — continuity often helps
- If effectiveness has declined, consider: (1) extended drug holiday (4-6 weeks off), (2) cycling through different formulations (immediate-release, extended-release, sublingual), (3) reassessing dose — often lower dose restores effectiveness after downregulation
Pre-pregnancy considerations: melatonin is not generally recommended during pregnancy due to limited safety data and theoretical concerns about fetal circadian development. Women in active fertility-seeking or who become pregnant should discontinue melatonin unless specifically directed otherwise by physician (some IVF protocols use melatonin for oocyte quality, but only under reproductive endocrinology direction).
CYP1A2 genetic-variant considerations: ultra-slow CYP1A2 metabolizers (common polymorphism) can experience dramatically elevated melatonin exposure at standard doses; starting at 0.3mg is appropriate for this population if identified.
Never combine with fluvoxamine without specific dose adjustment — 17-23× exposure elevation can produce persistent next-day sedation and paradoxical sleep disruption.
Oncology patients on tamoxifen, aromatase inhibitors, or hormone therapies: melatonin-estrogen interactions are complex and evolving; oncology team consultation essential before initiating melatonin in these populations.
Commonly Stacked With
Melatonin stacks thoughtfully with several evidence-based sleep and relaxation compounds, with the critical caveat that timing and dose-matching matter more for melatonin than for most other supplements. The single most important stacking principle: keep the melatonin dose low (0.3-1mg) and let other compounds do the heavier sedative lifting; high-dose melatonin in combination stacks often produces morning grogginess without additional benefit.
Melatonin + Magnesium (particularly magnesium glycinate 200-400mg): widely used and evidence-supported sleep stack. Magnesium glycinate provides both magnesium's GABA-A positive allosteric modulation and glycine's own sleep-promoting effects; melatonin provides circadian signaling. The combination addresses different aspects of sleep architecture — magnesium reduces sleep fragmentation and improves deep-sleep percentage, while melatonin primarily improves sleep onset and circadian alignment. Typical dosing: melatonin 0.3-1mg + magnesium glycinate 200-400mg elemental magnesium, 30-60 minutes before bed.
Melatonin + Glycine (3g sublingual or dissolved in water): Inagawa et al. 2006and subsequent trials documented that glycine 3g 30-60 minutes before bed produces subjective improvements in sleep quality, reduced sleep onset latency, and improved daytime alertness. Glycine appears to act via NMDA receptor modulation and a modest hypothermic effect that supports sleep onset. Combined with low-dose melatonin, the pairing addresses both sleep architecture and circadian timing. Typical stack: melatonin 0.5mg + glycine 3g, 30-60 minutes before bed.
Melatonin + L-theanine (200-400mg): L-theanine promotes alpha-wave EEG activity and mild relaxation without sedation, reducing sleep-onset rumination and anxiety-related sleep disruption. The combination pairs circadian signaling (melatonin) with arousal reduction (theanine), particularly effective for individuals whose sleep difficulty involves anxious thinking or racing mind.
Melatonin + Ashwagandha (300-600mg KSM-66 extract): addresses the cortisol-side of sleep difficulty. Ashwagandha reduces evening cortisol and HPA-axis activation; melatonin provides circadian signal. Useful for stress-related insomnia. Typical dosing: ashwagandha 300-600mg in evening (6-7pm) + melatonin 0.5-1mg 30-60 minutes before bed.
Melatonin + 5-HTP (50-100mg): 5-hydroxytryptophan is the precursor to serotonin (which is in turn the precursor to melatonin). This stack provides both the endogenous-synthesis substrate (5-HTP → serotonin → melatonin pathway supports overnight endogenous melatonin production) and exogenous melatonin for initial sleep onset. Particularly useful for individuals with suspected low endogenous melatonin production. Caution: avoid combining with SSRIs or MAOIs (theoretical serotonin syndrome risk). Typical dosing: 5-HTP 50-100mg + melatonin 0.3-0.5mg, 30-60 minutes before bed.
Melatonin + Vitamin D (2,000-5,000 IU daytime): not a direct sleep stack but addresses the bidirectional relationship between vitamin D status and sleep quality. Vitamin D deficiency is associated with worse sleep quality and increased insomnia; vitamin D supplementation in deficient individuals often improves sleep independently. Combining optimal vitamin D status with appropriate melatonin use addresses two distinct sleep-relevant biological inputs.
Melatonin + Magnesium Threonate (144mg elemental Mg): the threonate form crosses the blood-brain barrier better than other magnesium forms and may be preferable for cognitive-sleep applications where neuronal magnesium is the specific target.
Melatonin + caffeine timing management: melatonin's effects are significantly reduced by afternoon/evening caffeine, which delays endogenous melatonin onset and antagonizes adenosine-mediated sleep pressure. Users should observe a caffeine cutoff 6-8 hours before intended sleep to avoid blunting melatonin's effects. Morning caffeine doesn't interfere.
Melatonin + bright light management: the most potent non-pharmacological chronobiotic is morning bright light exposure (30-60 minutes of 10,000+ lux light within the first hour of waking). Combined with evening melatonin, this produces maximal circadian phase advances for DSPS. Conversely, evening blue-enriched light suppresses endogenous melatonin — screen use, LED household lighting, and late-evening light exposure reduce both endogenous and exogenous melatonin effectiveness.
Melatonin + GABA or L-theanine + passionflower: combination products marketed for sleep typically include melatonin with GABA-acting ingredients; evidence for the individual additions is variable. GABA itself has limited oral bioavailability and unclear CNS penetration.
Stacks to avoid or use with caution: Melatonin + benzodiazepines or Z-drugs produces additive sedation, generally safe but potentially unexpected morning grogginess. Melatonin + fluvoxamine produces 17-23× exposure elevation — clinically important, typically warranting dose reduction or alternative sleep approach. Melatonin + alcohol: alcohol disrupts REM architecture and sleep consolidation; combining with melatonin doesn't fully compensate for alcohol's sleep-architecture damage. Melatonin + warfarin: monitor INR. Melatonin + immunosuppressants: discuss with transplant team.
Anti-stacks for daytime use: some users take low-dose melatonin during daytime for anxiolysis or mood effects — this is generally unwise, as it disrupts endogenous circadian rhythm by creating "biological night" during biological day, often producing next-night sleep disruption. Daytime anxiolysis is better addressed by L-theanine, Ashwagandha, or Magnesium.
Timing is everything: melatonin is a circadian signal, not a sedative. Take it at a consistent time each night (within 30 minutes), tied to target sleep onset, and give it 30-60 minutes to work rather than expecting immediate sedation.
Side Effects & Safety
Contraindications
**Melatonin has few absolute contraindications** but multiple relative contraindications, interactions, and special-population considerations warranting caution. **Relative contraindications warranting specific caution**: **Pregnancy and lactation**: insufficient safety data for routine use. Melatonin crosses the placenta and appears in breast milk; endogenous maternal melatonin plays roles in fetal circadian entrainment, and supraphysiological exogenous exposure is of unclear safety. Some IVF protocols use melatonin for oocyte quality under reproductive endocrinology supervision, but this is an exception. Women planning pregnancy, pregnant, or lactating should discontinue melatonin unless specifically directed otherwise by their physician. **Children under 4 years**: not recommended outside specific physician-directed indications. Between ages 4-18, use is increasingly common for ASD/ADHD-related sleep disorders under pediatrician guidance, with doses typically 0.5-5mg and regular reassessment. Long-term effects on pubertal development remain theoretical concern without conclusive pediatric data beyond 5-10 years of use. **Autoimmune diseases** (rheumatoid arthritis, lupus, multiple sclerosis, Crohn's, autoimmune thyroid disease): theoretical concern that melatonin's immunostimulant effects on Th1 pathways could exacerbate autoimmune activity. Evidence is limited and mixed — some studies suggest benefit in specific autoimmune conditions, others suggest caution. **Discuss with rheumatologist or immunologist before initiating**, particularly in active disease phases or during immunosuppressive therapy adjustments. **Hormone-sensitive conditions**: melatonin modulates HPG-axis hormones, suppresses LH in some contexts, and has complex interactions with estrogen and androgen signaling. Patients with hormone-sensitive cancers (breast, prostate, endometrial, ovarian) should discuss with oncology team — melatonin may be beneficial as adjunct in some protocols but inappropriate in others. Endometriosis, severe PCOS, and menstrual-cycle abnormalities warrant reproductive endocrinology consultation. **Bipolar disorder**: rare reports of melatonin triggering or worsening mood episodes (particularly depressive or mixed states). Patients with bipolar disorder or family history should use melatonin cautiously and discontinue if mood changes occur. **Seizure disorders**: mixed evidence. Some animal and human data suggest melatonin has anticonvulsant properties; other reports have documented seizure threshold reduction in susceptible patients. Epilepsy patients should discuss with neurology before initiating. **Diabetes**: melatonin affects glucose metabolism in complex ways — large evening doses can blunt morning glucose regulation in some individuals. Type 2 diabetes patients starting melatonin should monitor morning glucose; dose adjustments of diabetes medications may be warranted. **Hypertension on antihypertensive therapy**: melatonin produces modest blood pressure reduction; combining with antihypertensives may produce additive effect. Monitor BP when starting melatonin. **Active transplant recipients**: immunosuppressant drug interactions (cyclosporine, tacrolimus, mTOR inhibitors) — discuss with transplant team. **Renal impairment (CKD stages 3-5)**: melatonin is largely hepatically cleared, but accumulation of metabolites in severe renal disease is possible; dose reduction may be prudent in stage 4-5 CKD. **Liver disease**: melatonin is extensively metabolized by hepatic CYP1A2 and CYP2C19. Cirrhosis, severe hepatic dysfunction, or active hepatitis may reduce clearance substantially; start at lowest doses (0.3mg) and titrate cautiously. **Major surgery (within 24 hours)**: discontinue melatonin 24 hours before major surgery given theoretical concerns about bleeding, sedation interaction with anesthesia, and immune modulation. Resume post-operatively per surgeon guidance. **Drug interactions warranting attention**: **Fluvoxamine (Luvox) and other strong CYP1A2 inhibitors** (ciprofloxacin, some quinolones, rofecoxib): can increase melatonin AUC **17-23 fold**. **This is clinically significant** — combining fluvoxamine with even 1mg melatonin produces plasma levels equivalent to 17-23mg, with persistent next-day sedation. Dose reduction or alternative sleep approach warranted. **Warfarin**: case reports of INR elevation with melatonin initiation. Monitor INR in the 2-4 weeks after starting or changing melatonin dose. **Benzodiazepines, Z-drugs, sedating antihistamines**: additive sedation, generally safe but potential for unexpected morning grogginess. Consider dose reduction of one or both. **Alcohol**: disrupts sleep architecture; combining with melatonin doesn't prevent alcohol's sleep fragmentation. Minimize alcohol use in individuals managing sleep issues with melatonin. **Immunosuppressants**: theoretical interaction; discuss with prescribing specialist. **Oral contraceptives**: estrogen inhibits CYP1A2 modestly, raising melatonin exposure; usually not clinically significant. **Caffeine**: antagonizes adenosine-mediated sleep pressure and delays endogenous melatonin onset; maintain afternoon caffeine cutoff. **Nifedipine**: some evidence of reduced nifedipine effect with melatonin; monitor BP. **SSRIs, SNRIs, tricyclics**: generally compatible; theoretical serotonin pathway considerations rarely clinically significant. Monitor for excessive sedation or paradoxical stimulation. **MAOIs**: theoretical interaction; caution recommended given MAOI's overall tight dietary and drug interaction restrictions. **Tamoxifen and aromatase inhibitors**: melatonin-estrogen interactions complex; oncology team supervision essential. **Absolute contraindications**: none in the strict sense. However, melatonin should not be used in: - Known hypersensitivity to melatonin or product excipients - Active fluvoxamine therapy without dose adjustment - Pregnancy without specific physician direction - Children under 2 years (except rare physician-directed specialized indications) **When to stop melatonin and seek medical evaluation**: - Persistent insomnia despite 4 weeks of appropriate melatonin use (consider sleep study, evaluation for sleep apnea, RLS, depression, or chronobiotic disorder) - Development of daytime sedation, cognitive impairment, or mood decline - Paradoxical worsening of sleep - New or worsening depression or anxiety symptoms - Development of vivid nightmares that don't resolve with dose reduction - Unexpected morning or daytime sedation suggesting drug interaction - Development of jaundice, persistent GI symptoms, or unusual bleeding/bruising - Pregnancy or pregnancy planning - Any major new medication addition warranting interaction review This is general educational content, not individualized medical advice. Individuals with chronic sleep difficulties, medical conditions, or on multiple medications should consult their physician before initiating melatonin. Melatonin is a hormone with metabolic, reproductive, immune, and chronobiotic effects, and its long-term use warrants periodic clinical reassessment rather than indefinite unsupervised use.
Additional Notes
Dosing melatonin requires distinguishing physiological replacement doses from supraphysiological pharmacological doses, and matching timing to indication.
Physiological replacement dose range (0.1-0.5mg): achieves plasma concentrations similar to endogenous nighttime peak (60-70 pg/mL in healthy adults); the appropriate range for most primary insomnia and jet lag applications. Studies including Brzezinski et al. 2005 meta-analysis (PMID: 15649737) suggest no advantage to doses above 1mg for sleep onset latency outcomes. 0.3mg melatonin is available from specialty manufacturers; 0.5mg is increasingly common in OTC products; 1mg represents a slight supraphysiological dose often used as a starting point.
Low pharmacological range (1-3mg): produces plasma peaks 3-5× endogenous night peak, appropriate for jet lag, modest phase-shifting, and some DSPS protocols. Most OTC products in this range.
Moderate pharmacological range (3-10mg): produces plasma peaks 10-25× endogenous night peak; no additional sleep benefit over lower doses but may be appropriate for REM behavior disorder, migraine prophylaxis (3mg), and high-dose cycling in specific contexts. Common OTC dose — generally too high for routine sleep use.
High pharmacological range (10-40mg): reserved for oncology adjunctive protocols, some RBD cases, and specialized research applications; physician-directed only.
Timing by indication:
- Primary insomnia/sleep onset: 30-60 minutes before desired sleep onset; consistent timing within 30 minutes night-to-night
- Jet lag (eastward, ≥5 zones): 30 minutes before destination-time-zone bedtime, starting night of arrival, continuing 3-4 nights; pre-departure dosing optional
- DSPS phase advance: 5-7 hours before current habitual sleep onset (not target bedtime) — this timing is counterintuitive and essential; typical 4-8pm dosing for 3am habitual onset
- REM behavior disorder: bedtime; extended-release preferred for overnight coverage
- Migraine prophylaxis: bedtime, nightly consistent
- Oncology adjunctive: bedtime; high doses typically before sleep
Formulation choices:
Immediate-release (IR) tablets: peak plasma 45-90 min, half-life 35-50 min; best for sleep onset latency but may not provide overnight coverage. Most common OTC product. 0.3-1mg IR is the standard starting point for most users.
Extended-release (ER): sustained 2-6 hour plasma elevation; better for sleep maintenance and RBD coverage. Circadin (EU prescription, 2mg ER), Slenyto (pediatric ER 1-5mg), and multiple OTC ER products available. For users with early-morning awakening alongside sleep-onset difficulty, ER may be preferred. For pure sleep-onset issues, ER offers no advantage and may increase morning grogginess.
Sublingual: faster absorption than oral (peaks 20-40 min), useful for users with significant first-pass metabolism or who need rapid onset. Often preferred for occasional use. Dose typically 0.5-3mg.
Liquid/spray: rapid absorption, easy dose titration; favored for pediatric use and for precise micro-dosing.
Gummies: convenient but often contain sugar, variable actual content (NOCA 2023 analyses have documented melatonin gummy content 74-347% of label claim in some products — significant concern for pediatric use). Prefer reputable third-party tested brands.
Transdermal patches: marketed but limited pharmacokinetic validation; not generally recommended.
Lab monitoring and dose individualization: routine lab monitoring is not required for standard sleep-dose use. For specialized applications: (1) salivary DLMO (dim light melatonin onset) measurement can guide DSPS protocol timing — available through specialized labs; (2) 24-hour urinary 6-sulfatoxymelatonin quantifies endogenous production; (3) in high-dose oncology use, monitor reproductive hormones and ACTH axis. For most users, sleep diary endpoints (sleep onset latency, wake-ups, subjective quality, morning alertness) are the practical response measurement.
Age considerations: endogenous melatonin declines with age — total nightly production in healthy 60-year-olds is approximately 40-50% of young-adult levels, and by 80+ is typically <25% of young-adult levels. This endocrine decline is part of why sleep architecture changes with aging and is a rationale for considering melatonin supplementation in older adults with sleep complaints. Older adults may benefit from slightly higher doses (0.5-2mg) than younger adults, though the principle of starting low remains.
Storage: store tablets at room temperature in tightly sealed containers away from light. Melatonin is photosensitive — opaque containers preferred, dark storage for bulk products. Typical shelf life 2-3 years; do not use past expiration. Liquid and sublingual products may have shorter shelf life.
Product quality concerns: OTC melatonin product quality is inconsistent — a 2017 analysisfound melatonin content ranging from 17% to 478% of label claim across commercial products, with many products also containing significant serotonin contamination. Prefer reputable brands with third-party testing (USP verification, NSF certification, or ConsumerLab analysis); avoid gummies and combination products with unverified content.
Genetic and metabolic variation: CYP1A2 polymorphisms substantially affect melatonin metabolism — ultra-slow metabolizers can experience 2-3× higher exposure than rapid metabolizers at the same dose. If side effects (grogginess, vivid dreams) are prominent at standard doses, consider 0.3mg as a starting point; if effects are minimal, a rapid-metabolizer phenotype may explain the need for higher doses.
Frequently Asked Questions
What is the recommended Melatonin dosage?
Dosage for Melatonin varies by protocol. Consult a qualified healthcare provider.
How often should I take Melatonin?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Melatonin need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Melatonin side effects?
**Melatonin has an exceptionally wide safety margin** and has been used in clinical doses up to 300mg/day in oncology protocols without serious acute toxicity. However, **side effects are common at supraphysiological doses** (3mg and above) and are often misattributed to insomnia or unrelated causes: **Morning grogginess (drowsiness, "hangover," brain fog)** is the most common complaint and is predominantly dose-related. Supraphysiological plasma levels (from 3-10mg doses) that persist into morning hours produce residual sedation, reduced morning alertness, delayed peak cognitive performance, and sometimes subjective depressive or flat mood. This is largely eliminated by dropping to 0.3-1mg, using immediate-release rather than extended-release formulations for most users, and timing the dose at least 30 minutes before intended sleep (not during the night if wakeful). **Vivid dreams and nightmares** are reported by 10-20% of users at 3-10mg doses, reflecting increased REM sleep pressure and altered REM architecture at high doses. Some users find the dream intensification positive; others find it disruptive. Nightmare frequency typically resolves within 2-3 weeks of continued use or with dose reduction to 0.3-1mg. **Paradoxical insomnia and fragmented sleep** occur in a minority of users and appear related to individual differences in receptor sensitivity, metabolism, and timing. Some individuals wake repeatedly after taking melatonin, particularly at higher doses; for these users, lower dose (0.3-0.5mg), earlier timing (4-5 hours before bed), or discontinuation is appropriate. Paradoxical insomnia is particularly reported in individuals with anxiety-spectrum disorders. **Headache** is reported in 5-10% of users, typically mild and self-limited, more common at higher doses. **Mood effects**: most users report neutral or mildly positive mood effects from appropriately-dosed evening melatonin. However, a minority report lowered mood, increased fatigue, or depression-like symptoms at high doses (particularly 5-10mg), which may reflect melatonin's interaction with the serotonin system and/or disruption of dopamine signaling in susceptible individuals. Users with histories of major depression should approach melatonin cautiously and discontinue if mood worsens; seasonal-affective-spectrum individuals may be particularly sensitive. **Gastrointestinal effects** (nausea, abdominal discomfort, diarrhea) are uncommon but reported, typically at higher doses. **Modest hypothermia**: evening melatonin produces a small drop in core body temperature (0.2-0.4°C), which is physiological and usually unnoticed but can be bothersome for some users. **Hormonal effects**: melatonin interacts with reproductive-axis hormones (suppresses LH in some contexts), growth hormone secretion (modest effects), and cortisol rhythm. These are usually subclinical but may be relevant in fertility planning, pregnancy, and hormone-sensitive conditions. Melatonin is a natural reproductive signal in seasonal breeders and long-term high-dose use theoretically could affect human reproductive physiology; the evidence is limited but supports caution in pregnancy, lactation, and fertility-seeking cycles. **Drug interactions**: The most clinically significant interaction is with **fluvoxamine** and other potent **CYP1A2 inhibitors** (ciprofloxacin, some antipsychotics), which can elevate melatonin exposure 17-23 fold — combining melatonin with fluvoxamine produces supraphysiological concentrations even from nominal 1mg doses. **Warfarin** metabolism may be affected (isolated reports of INR changes); patients on warfarin should monitor INR if starting melatonin. **Benzodiazepines and Z-drugs** combine additively with melatonin for sedation, generally safe but may produce unexpected morning sedation. **Antihypertensives**: melatonin's modest blood pressure-lowering effect may combine additively; monitor BP when starting melatonin in treated hypertension. **Oral contraceptives**: estrogen component inhibits CYP1A2, modestly raising melatonin exposure; usually not clinically significant. **Immunosuppressants**: theoretical concern that melatonin's immunomodulatory effects could interact with cyclosporine, tacrolimus, or other immunosuppressants; discuss with transplant or rheumatology team. **Nifedipine** effect may be reduced by melatonin in some studies. **SSRIs and tricyclic antidepressants**: generally compatible but monitor for excessive sedation or paradoxical stimulation. **Pediatric safety**: extensive pediatric use over the past two decades, particularly for ASD/ADHD-related sleep disorders, has revealed a generally favorable pediatric safety profile. However, concerns about long-term effects on pubertal development remain based on animal data suggesting melatonin modulates reproductive-axis hormones. Pediatric use is considered appropriate by many pediatricians when sleep problems are significant and behavioral measures have failed, at doses of 0.5-5mg under guidance, with periodic reassessment. Long-term pediatric safety data beyond 5-10 years is limited. **Overdose**: even very high single doses (up to 300mg) have not produced serious toxicity in documented cases. Accidental pediatric ingestions of adult supplement doses (10-20mg) typically produce only increased drowsiness and GI upset, managed supportively. The practical implication: melatonin has an extraordinarily wide therapeutic window compared to traditional sedatives. **Long-term safety**: while short-term studies are generally reassuring, **long-term daily use beyond 1-2 years has limited controlled study** in adults and particularly in pediatric populations. Theoretical concerns about pituitary-gonadal axis effects, receptor desensitization, and unknown long-term circadian consequences warrant periodic drug holidays or re-evaluation of ongoing need. Most sleep specialists recommend using melatonin as a time-limited intervention (jet lag, phase-shift correction, bridging to better sleep habits) rather than indefinite nightly use.
Where can I buy Melatonin?
Visit our vendor directory to find trusted sources for Melatonin.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
